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Abstract 
Background: Evaluation of local Plasmodium falciparum malaria transmission has been investigated previously using 
the reversible catalytic model based on prevalence of antibody responses to single antigen to estimate seroconver‑
sion rates. High correlations were observed between seroconversion rates and entomological inoculation rates (EIR). 
However, in this model, the effects of malaria control interventions and clinical episodes on serological measurements 
were not assessed. This study monitors the use of antibody responses to P. falciparum crude extracts for assessing 
malaria transmission, compares seroconversion rates estimated from longitudinal data to those derived from cross‑
sectional surveys and investigates the effects of malaria control interventions on these measures in an area of declin‑
ing malaria transmission. In addition, the validity of this model was evaluated by comparison with the alternative 
model.
Methods: Five cross‑sectional surveys were carried out at the end of the wet season in Dielmo, a malaria‑endemic 
Senegalese rural area in 2000, 2002, 2008, 2010 and 2012. Antibodies against schizonts crude extract of a local P. 
falciparum strain adapted to culture (Pf 07/03) were measured by ELISA. Age‑specific seroprevalence model was used 
both for cross‑sectional surveys and longitudinal data (combined data of all surveys).
Results: A total of 1504 plasma samples obtained through several years follow‑up of 350 subjects was used in this 
study. Seroconversion rates based on P. falciparum schizonts crude extract were estimated for each cross‑sectional 
survey and were found strongly correlated with EIR. High variability between SCRs from cross‑sectional and longi‑
tudinal surveys was observed. In longitudinal studies, the alternative catalytic reversible model adjusted better with 
serological data than the catalytic model. Clinical malaria attacks and malaria control interventions were found to 
have significant effect on seroconversion.
Discussion: The results of the study suggested that crude extract was a good serological tool that could be used to 
assess the level of malaria exposure in areas where malaria transmission is declining. However, additional parameters 
such as clinical malaria and malaria control interventions must be taken into account for determining serological 
measurements for more accuracy in transmission assessment.
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Background
Falciparum malaria remains a public health priority and 
a major cause of morbidity and mortality in tropical areas 
[1]. The observed pathophysiology of Plasmodium fal-
ciparum malaria infection is strongly dependent upon 
endemicity, age and level of immunity [2]. In malaria 
endemic areas, where transmission is perennial and sta-
ble, parasitic tolerance has been described and explained 
by a partial immunity acquired over years [3, 4]. Age is, 
therefore, a major indicator of the duration of exposure 
to malaria parasite. However, acquired immunity is not 
completely protective but can be effective against clinical 
symptoms and severe form of the disease [5].
Several interventions have been implemented during 
the two last decades in the fight against malaria. These 
interventions include treatment by artemisinin-based 
combination therapy (ACT), use of long-lasting insecti-
cide-impregnated bed nets for exposed populations and 
use of rapid diagnostic tests for malaria diagnosis. These 
interventions led to considerable reduction in the num-
ber of clinical episodes and deaths due to malaria [1]. 
Despite the significant progress achieved, the disease 
remains a major problem. The World Health Organiza-
tion (WHO) reported 212 million clinical malaria cases 
and 429,000 deaths in 2015. Children under 5 years old 
are particularly susceptible to malaria illness, infection 
and death. In 2015, malaria killed an estimated 303,000 
under-fives globally, including 292,000 in the African 
Region [1].
Monitoring malaria transmission intensity and 
strengthening malaria control measures are necessary 
since incidence of severe disease and mortality increase 
with transmission intensity [6–8]. The ongoing changes 
in malaria endemicity become a key determinant of the 
progress achieved. Moreover these changes determine 
the time required to reach the step where elimination 
could be foreseen [9]. Standard measurements of malaria 
transmission based on entomological inoculation rate 
(EIR) and parasite prevalence are expensive, time-con-
suming and lack of precision because of micro-heteroge-
neity of malaria transmission [10–12]. In addition, both 
EIR and parasite prevalence are affected by seasonality 
[13, 14]. Furthermore, assessing malaria transmission 
intensity and evaluating the impact of interventions are 
complicated in areas where transmission has been sub-
stantially reduced. Therefore, alternative approaches are 
required to assess malaria transmission and evaluate 
intervention programmes.
The use of mathematical models and prevalence of anti-
malarial antibodies constitute alternative approaches 
to evaluate malaria endemicity [15, 16]. Mathemati-
cal models allow the determination of seroconversion 
rate (SCR) and seroreversion rate (SRR) which are, for a 
given time interval, the rates with which a seronegative 
subject becomes seropositive and a seropositive sub-
ject turns back to seronegative, respectively. Predictive 
seroprevalence (prevalence of antibody responses) can 
be calculated by using maximum likelihood methods. 
Seroprevalence reflects cumulative exposure and thus is 
less affected by seasonality because antibody responses 
can persist for years after infection. Serological mark-
ers have been previously used to assess malaria trans-
mission intensity [15–17], to detect recent changes in 
malaria endemicity [17, 18], to evaluate effectiveness of 
malaria eradication efforts [19, 20], and SCR has been 
shown to correlate with EIR [15]. However, these single 
antigen-based serological approaches have significant 
limitations related to the sensitivity of the assay and the 
antigenic polymorphism that may affect detectable anti-
body responses [21–23].
An alternative method could be the use of a combi-
nation of antigens rather than a single one since recent 
studies have shown that responses to crude parasite 
extract or multiple antigens can overcome [17, 24, 25] 
these limitations.
Almost all reported mathematical approaches used the 
catalytic model without considering the effect of several 
factors (covariates). Taking these covariates into account 
could improve the effectiveness of serological models in 
assessing the intensity of malaria transmission [15, 16, 18, 
25–29].
Incorporation of covariates such as the number of clin-
ical attack or the use of long-lasting insecticide-impreg-
nated bed nets (LLIN) in the model, allows to take into 
account the heterogeneity of the population and the 
effect of interventions affecting malaria transmission.
Previous studies have estimated SCR with reversible 
catalytic model using cross-sectional surveys and high 
correlation was shown between serological measure-
ments of transmission and EIR [15, 16, 18]. However, 
given the fact that longitudinal surveys are often con-
sidered in sero-epidemiological studies and the increas-
ing use of cross-sectional serological data to investigate 
malaria transmission, it would be important to assess 
consistency of cross-sectional results with SCR esti-
mated from longitudinal survey in order to validate 
this approach. In this context, Arnold et  al. [30] inves-
tigated catalytic model in longitudinal cohort in order 
to validate this approach. The authors compared SCR 
using antibody responses against the merozoite surface 
 protein1–19 antigen measured in a prospective longitu-
dinal cohort of children aged 0–11 years old to SCR cal-
culated in a cross-sectional survey in a different group 
ranging from 0 to 90 years old. The comparison between 
the two approaches was done exclusively in children up 
to 11 years.
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One of the objectives of the present study was to 
explore if the incorporation of some variations such as 
allowing age-varying to SCR or adding covariates in the 
reversible catalytic model could improve the precision or 
accuracy of exposure estimates using serological meas-
urement of antibody responses to whole parasite extract. 
The availability of longitudinal data on a cohort whose 
age ranged from 0 to 90 years allowed the analysis of SCR 
and SRR values in different age group as studies have 
shown that antibody responses conversion and reversion 
varied with age and antigen [31–34].
A second objective of this study was to investigate the 
utility of P. falciparum crude schizonts extract which is 
a mixture of antigens, to monitor malaria transmission 
intensity and to detect temporal changes in malaria epi-
demiology in Dielmo, a Senegalese rural holoendemic 
area, using the age-specific reversible catalytic model 
described in previous studies [15, 16]. In Dielmo village, 
various malaria control interventions have been imple-
mented since 2000, leading to significant reduction in 
malaria transmission and incidence [35]. Thirdly, the 
effects of potential covariates such as malaria control 
interventions and clinical malaria attacks on the SCR and 
SRR were investigated. Lastly, the use of cross-sectional 
data versus longitudinal data was also analysed and a 
comparison was performed between reversible catalytic 
model and alternative catalytic model in longitudinal 
data for assessing transmission evolution through SCR or 
SRR.
Methods
Study area and population
In this study, sera collected during five cross-sectional 
surveys in 2000, 2002, 2008, 2010 and 2012 from indi-
viduals living in Dielmo were used. Villagers are followed 
up longitudinally since 1990 as part of the Dielmo project 
[36, 37].
Different interventions were implemented based on 
recommendations from the National Malaria Control 
Programme. Treatments included the use of chloroquine 
in 2000, replaced by the association amodiaquine plus 
sulfadoxine–pyrimethamine from November 2003 to 
May 2006, followed by the introduction of artemisinin-
based combination therapy (ACT) since June 2006. 
LLINs have been deployed since 2008. As a result, the vil-
lage has experienced a dramatic decrease of the different 
malaria indicators monitored [35]. The incidence of clini-
cal malaria dropped from 771 in 2000 to only 17 cases 
in 2012 [35]. Malaria transmission decreased consider-
ably with EIR dropping from 500 infective bites/person/
year in 2000 to 7.6 infective bites/person/year in 2012 
[35]. For the longitudinal study, cross-sectional data were 
combined and only people who have at least two sera 
observations during the survey periods were considered 
in the longitudinal analysis. A total of 1147 sera obtained 
from 359 subjects aged 0–91 years old were used in the 
longitudinal analysis.
Laboratory methods
Plasmodium falciparum crude schizonts extract obtained 
from a culture-adapted P. falciparum strain (Pf 07/03) 
isolated from an inhabitant of Dielmo, was used as anti-
gens for serological investigations. Procedures of P. falci-
parum culture and crude extract schizonts (Sch 07/03) 
preparations have been described previously [38]. Anti-
body responses were assayed by ELISA, the cut-off value 
for positive antibody response was defined as previously 
described [38]. Briefly, antibody responses were consid-
ered positive if the optical density ratio (OD ratio = mean 
OD value of sample divided by mean OD value of naïve 
sera) was above two.
Statistical analysis
Antibody levels comparison
Comparisons of OD ratio of antibody responses were 
assessed using Kruskal–Wallis rank test and this has been 
presented in a previous study [39]. Three age groups were 
studied: under 5, 5–15 years old and above 15 years old. 
Odds ratio for prevalence was determined using a simple 
logistic regression. Seroprevalence was estimated by the 
proportion of seropositive participants. Kruskal–Wal-
lis rank test was used to compare ODs between surveys. 
Chi Square and Fischer exact tests were used to compare 
seroprevalences between age groups. All statistics were 
done using R software [40].
Reversible catalytic prevalence models for cross‑sectional 
data
Seroconversion and seroreversion rates were calculated 
using the five observed cross-sectional data separately. 
At first instance, a previously described age specific 
reversible catalytic conversion model [15, 16, 18] was 
adjusted to the binary sero-immunological data (anti-
body responses to crude P. falciparum schizonts extract) 
to estimate seroconversion (λ) and seroreversion (ρ) rate, 
respectively. For each cross-sectional survey, seropreva-
lence has been calculated as described by Corran et  al. 
[15] according to the following formula:
λ: the annual seroconversion rate, ρ: the annual serore-
version rate, P(a): seroprevalence for a given age a.
Seroconversion and seroreversion rates represent 
respectively the force of exposure to malaria parasites 
over time relative to the intensity of infection in malaria 
P(a) =

+ ρ
(1− exp (−(+ ρ)a))
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endemic areas and the persistence of antibody response 
[16]. Secondly, an age specific variation in seroconver-
sion rate (λ) and seroreversion rate (ρ) was investigated 
by adjusting an alternative catalytic model in which λ and 
ρ were allowed to change at time-point. Comparison of 
these models was performed using likelihood ratio test.
Estimation of seroprevalence and seroconversion 
rates with longitudinal data using reversible catalytic 
and alternative catalytic prevalence models
Age-specific antibody seroprevalence and seroconversion 
in longitudinal study were estimated by combining meas-
urements obtained from all five cross sectional surveys. 
In order to select the best model for the serological longi-
tudinal data, two approaches were used. First, a catalytic 
model and an alternative catalytic model were applied 
and λ (seroconversion rate) and ρ (seroreversion rate) 
were allowed to change at time-point without covariates. 
Second, these two models with covariates were applied to 
investigate factors that could influence both seroconver-
sion (λ) and seroreversion (ρ) rates. In this study, covari-
ates which were incorporated in the models were clinical 
malaria episode and use of bed nets. In these models 
seroconversion (λ) and seroreversion (ρ) rates were cal-
culated respectively by:
where λ0(t) and ρ0(t) were annual conversion rate from 
seronegative to seropositive (without covariate effect) 
and annual reversion rate from seropositive to seronega-
tive (without covariate effect), respectively. This model 
is similar to the one described by Sepulveda et  al. [41], 
though the authors did not describe a model that allowed 
the SCR to vary by covariates. The regression coefficients 
(t) = 0 ∗ exp(β1 ∗ clinical episode
+ β2 ∗ use of mosquito bed nets)
ρ(t) = ρ0 ∗ exp(β
′
1 ∗ clinical episode
+ β ′2 ∗ use of mosquito bed nets)
(β1, β2, β′1, β′2)can be interpreted in terms of relative risk 
(RR) similarly to regression coefficient in the propor-
tional hazards regression model of Cox [42]. Likelihood 
ratio test (LRT) and Wald test were used to assess the 
effect of covariates and to select the parsimonious model. 
Significant cut-off was fixed at 0.05 (p < 0.05). The goal 
here was to assess the effect of clinical malaria attacks 
and LLIN-based malaria control interventions on SCR. 
The reversible catalytic and alternative reversible cata-
lytic models are detailed in Additional file 1.
Comparison between observed and predicted seroprevalence
The observed seroprevalence and predicted seropreva-
lence were compared using Log likelihood ratio test. 
Predicted seroprevalence curves and 95% confidence 
intervals were plotted and the corresponding λ was calcu-
lated for each cross-sectional period and both cross-sec-
tional surveys combined. Seroprevalence using observed 
positive responses data were also represented. Wald test 
and likelihood ratio test (LRT) were used to test effects of 
covariates. All analyses were conducted using R software 
version 3.1.2 [40].
Results
Characteristics of the surveyed population
Table  1 presents epidemiological, demographical and 
clinical characteristics of the surveyed population. The 
age characteristics of the surveyed population were 
described in a previous study [39] Both total and mean 
number of clinical malaria episodes/person decreased 
over time. Prior to the introduction of LLINs in Dielmo 
in 2008, the maximum number of clinical malaria 
attacks varied between 14 and 17 episodes/person/year). 
Importantly, the maximum number of clinical malaria 
episodes/person decreased dramatically after the intro-
duction of LLINs in the study site in 2008 [35] falling to 
2 and 1 episode in 2010 and 2012, respectively. Table  2 
describes the studied cohort; 35.1% of subjects were 
observed three times and 15.9% were observed five times 
during the study. Age medians were relatively similar for 
Table 1 Characteristics of survey participants
2000
(N = 436)
2002
(N = 372)
2008
(N = 538)
2010
(N = 576)
2012
(N = 548)
p value
Sex
 Male 53.7 (234) 48.4 (180) 47.6 (256) 47.2 (272) 45.6 (250)
 Female 46.3 (202) 51.6 (192) 52.4 (282) 52.8 (304) 54.4 (298) 0.091
Clinical malaria episodes/person
 Min 0 0 0 0 0
 Mean 1.6 1.1 1.09 0.20 0.03
 Max 14 17 13 2 1
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all screened times groups (Table 2), except the group that 
was observed five times during the survey period.
Prevalence of antibody responses to Sch 07/03 
amongst age groups
Prevalence of antibodies responses against P. falciparum 
crude schizonts extract decreased significantly over sur-
veys. Figure 1 shows the seroprevalence for each survey 
and by age group. Seroprevalence increased significantly 
with age per survey. Seroprevalence decreased over time 
during surveys in both children and adults. The reduc-
tion in seroprevalence was greater after the introduc-
tion of bet nets in the village in late 2008 for children 
and older children (5–15 years). For adults, reduction in 
seroprevalence was observed later after 2010. The pro-
portion of seropositive subjects varied from 97% in 2000 
to 72% in 2012. However, during the high transmission 
period in 2000, antibody responses were not different 
between older children (5–15 years) and adults whereas 
significant differences in seroprevalence were observed 
between these age groups in 2002, 2008, 2010 and 2012. 
Prevalence of antibodies was lowest among younger chil-
dren (0–5 years). In this age group (0–5 years), the high-
est percentage was observed in 2002 (4.57%), significantly 
different to the two other age groups. Of note, in the 
youngest age group, the already low seroprevalence con-
tinued to decrease after the introduction of mosquito 
nets in 2008 despite a small increase in 2012 (Fig. 1).
In older children (5–15  years), seroprevalence 
decreased from 2000 to 2010 with a high rate of decay 
between 2008 and 2010 (79.27% of responders in 2008 
and 50.98% in 2010). The rebound observed in 2012 
in the young children (0–5 years) was also found in the 
older children group (5–15 years) (Fig. 1). For the adult 
group, seroprevalence decreased slightly between 2000 
and 2012. Despite the decrease observed before and after 
2008, the difference was not significant (p = 0.12).
Analysis of seroconversion rate and seroprevalence curves 
by cross‑sectional survey
Seroprevalence was estimated using an age-dependent 
model, a reversible catalytic conversion model described 
previously [16]. However, the SCR was not fixed to one 
value, but could be modified [16, 25]. Figure 2 shows an 
increase in proportion of seropositivity with partici-
pant’s age. Comparison of the different predicted curves 
at different time points showed a difference in the rate of 
acquisition of positive responses with a decreased rate 
from 2000 to 2012. However, visual assessment of the plot 
suggested a poor fitting of the model for all surveyed time 
points. For instance, the observed seroprevalence was 
lower than the predicted one for the younger age group.
Significant difference of SCRs were observed between 
2000 and 2008 (p = 0.024) and between 2002 and 2008 
(0.011). SCRs were highest before the introduction of 
LLINs in 2008 with SCR values of 0.22 [95% CI (0.173–
0.280)] and 0.126 [95% CI (0.099–0.159)] in 2000 and 
Table 2 Characteristics of the longitudinal cohort
Number of screened 
times during survey period
% of subjects (N = 359) Age median
2 30.6 (110) 12.8
3 35.1 (126) 12.3
4 18.4 (66) 12.5
5 15.9 (57) 36
Fig. 1 Seroprevalence to P. falciparum malaria schizonts sch07/03 with age groups by survey
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2002 respectively compared to 0.094 [95% CI (0.079–
0.112)] in 2008. In addition, a decrease of SCRs was 
observed after 2008 (Table 3). When an alternative cata-
lytic model that included age specific variation for sero-
conversion rate was used, the best adjustment to the real 
data (LRT, p  <  0.001) was observed as compared to the 
catalytic model with constant SCR and SRR.
Model applicability: correlation between SCR and EIR
A positive correlation was observed between EIR 
and SCR (λ) of antibodies against Pfsch07/03 
(r-square = 0.905, p = 0.024). This trend was also shown 
in Fig. 3a, which presents the evolution of observed EIRs 
and corresponding EIRs calculated from serological 
measures using the method described in previous stud-
ies, respectively [15, 16].
The concomitant decrease of both EIR and SCR (λ) 
during survey period suggested that serological data 
could be used to assess the level of malaria transmis-
sion intensity. Figure  3b shows EIRs estimated from 
SCRs of antibody responses to Pfsch07/03—compared to 
observed EIRs measured with entomological methods in 
the study site (Dielmo) over the 5 years of surveys [35]. 
Estimated EIR showed a greater variability across survey 
periods. Despite slight difference between observed EIR 
and estimated EIRs from all period except for 2002, the 
corresponding EIRs closely followed up trend of observed 
EIRs over the survey periods (Fig. 3a).
Figure  3c describes dynamics of both SCR and SRR 
over the period. Dramatic reduction was observed in 
estimates seroconversion rates (SCR). In seroreversion 
rates (SRR), a small reduction was observed over time 
until 2010 where a slight increase was found.
Analysis of seroconversion rate and seroprevalence curves 
in longitudinal survey
Seroprevalence results from catalytic model applied to 
longitudinal data are shown in Fig. 4a. A poor fitting of 
Fig. 2 Fitting seroprevalence by reversible catalytic model against Pf Sh07/03 for each cross‑sectional survey. Black dots represent the observed val‑
ues, red lines indicate estimated seroconversion with the model and black broken lines indicate the 95% confidence interval (CI) with the likelihood 
ratio test. The sixth plot present the correlation between the seroconversion rate and the observed EIR given by entomologists
Table 3 Seroconversion rates from  catalytic models 
in cross-sectional surveys, their corresponding EIR [15] cal-
culated from  the serological measures and  observed EIR 
given by entomologists
Surveys 
period
SCR (95% CI) Corresponding 
EIR
Observed EIR
2000 0.22 (0.17–0.280) 518.57 482.6
2002 0.126 (0.099–0.159) 261.77 409.9
2008 0.094 (0.079–0.112) 174.35 155.3
2010 0.073 (0.062–0.086) 116.97 88.8
2012 0.042 (0.036–0.049) 32.28 7.6
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age-seroprevalence of anti-Pfsch0703 was observed. 
Seroprevalence in adults group was under-estimated 
compared to younger age groups, which seemed to be 
over-estimated. Seroconversion and seroreversion rates 
estimated from the catalytic model was 0.284 and 0.066, 
respectively (Table 4).
Slight variation of SCRs and SRRs were observed when 
covariates such as clinical malaria attacks and LLINs 
usage were taken into account in the catalytic model in 
which SCR and SRR were estimated respectively at 0.284 
(0.230–0.351) and 0.041 (0.030–0.055). The LRT showed 
a significant difference between these models in favor of 
the model with covariates (p < 0.001).
Figure  4b presents results of the alternative catalytic 
model in which age-varying SCR and SRR are allowed. 
The LRT showed that the alternative model was signifi-
cantly better than the catalytic model in which SCR and 
SRR were constant (X2 = 25.67, p < 0.001). Current SCR 
(2012) using all sample surveys was calculated and found 
to be equal to 0.056 [95% CI (0.04–0.11)] from the alter-
native catalytic model and the corresponding SRR was 
0.01 [95% CI (0.0007–0.08)].
Comparison of SCR and SRR from longitudinal study versus 
cross‑sectional surveys
Table  4 shows comparison of SCR and SRR estimated 
from longitudinal surveys to those from the five cross-
sectional surveys by both catalytic models with and with-
out covariates. SCRs from longitudinal approach [SCR 
(without covariates)  =  0.284 (0.230–0.351) and SCR 
(with covariates)  =  0.215 (0.171, 0.269)] were almost 
equal to the SCR (0.220 (0.173, 0.280) from the cross-sec-
tional survey in 2000. For other cross-sectional surveys 
(2002, 2008, 2010 and 2012), there were a high variability 
Fig. 3 Trends of observed and estimated entomological inoculate rate (EIR), seroconversion rate (SCR) and seroreversion rate (SRR): a dynamic of 
observed entomological inoculate rate, EIR (black) calculated from parasitological measurements, seroconversion rate of anti‑Pfsch07/03 and their 
corresponding entomological inoculate obtained by the catalytic model described previously [15], b comparison between observed and corre‑
sponding EIR obtained by the log–log calibration [15, 16], c evolution of SCR and SRR by years
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between SCRs from cross-sectional and longitudinal sur-
veys. In contrast, for the alternative catalytic model with 
covariates current SCR estimated to 0.046 (0.003–0.052) 
was comparable to SCR value of 0.042 (0.036–0.049) 
from the cross-sectional survey in 2012 (Fig. 4b).
Effects of clinical malaria attack and malaria control 
interventions on seroconversion
To investigate respectively the impact of LLINs usage 
and clinical malaria episodes on SCR and SRR, catalytic 
age reversion model with covariates has been applied on 
data combined from all surveys. Table 5 summarizes the 
estimation of these parameters. The mosquito nets inter-
vention reduced the seroconversion rate, nevertheless it 
increased the seroreversion rate. A significant association 
was found between clinical episodes and SCR with a p 
value < 0.001.
Discussion
In malaria pre-elimination context with reduced clinical 
episodes and transmission intensity due to implemented 
strategies against the disease, standard assessment tools 
lack of sensitivity and more sensitive tools are necessary 
to accurately evaluate both the level of exposure and the 
impact of malaria control interventions. These tools can 
also help to detect resurgence in transmission intensity. 
In recent years, several studies described the estimation 
of malaria transmission using model based on the sero-
prevalence of antibody responses against recombinant 
blood stage antigens, such as MSP1, MSP2, AMA-1, 
MSP-1_19, GLURP [15–18, 27–30, 43, 44] and sporozo-
ite stage antigens of Plasmodium [45]. These serologi-
cal markers could be potentially sensitive, especially in 
areas of low transmission [29] as antibody responses, in 
particular to blood stage antigens, have been shown to 
persist for several years after transmission has ceased 
[46–49]. Thus, antibody responses against blood stage 
antigens could be detected even if transmission is lower. 
However, the use of specific single antigen might induce 
a lack of sensitivity and lead to a significant underestima-
tion of the immune response to P. falciparum infection. 
The variation in individual immune reactivity as well as 
the different duration of antibody responses against dif-
ferent antigens [34, 50] and antigenic polymorphism may 
Fig. 4 Fitting seroprevalence by reversible catalytic model (a) and alternative catalytic model (b) for anti‑Pf Sh07/03. For all these figures, the red 
curves were the seroprevalence obtained from models without covariates and their 95% likelihood ratio test confidence intervals and the green 
ones these from models according to the clinical attacks and the LLINs usage. The triangle points were the seroprevalences calculated among the 
observed antibodies response
Table 4 Estimation of  seroconversion and  seroreversion 
rates from longitudinal and cross-sectional studies
Study Seroconversion (95% 
CI)
Seroreversion (95% 
CI)
Longitudinal survey
 Without covariates 0.284 (0.230–0.351) 0.066 (0.051–0.085)
 With covariates 0.215 (0.171–0.269) 0.041 (0.030 ‑ 0.055)
Cross‑sectional surveys
 2000 0.220 (0.173–0.280) 0.006 (0.00–0.514)
 2002 0.126 (0.099–0.159) 0.001 (0.00–0.02)
 2008 0.094 (0.079–0.112) 0.017 (0.007–0.047)
 2010 0.073 (0.059–0.091) 0.003 (0.00–0.024)
 2012 0.042 (0.036–0.049) 0.057 (0.026–0.125)
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affect serological responses, thus the results obtained 
with specific recombinant antigens [21–23, 51]. As an 
example, Ondigo et  al. showed that antibody half-life 
may be short, intermediate or long depending on age and 
antigen and concluded for a need to associate antigen 
with similar half-life to improve precision and accuracy 
of malaria exposure estimates [52]. Recently, Helb et al., 
in a study aimed at improving tools to reliably measure 
P. falciparum exposure, observed that P. falciparum-spe-
cific antibody responses differ by antigen and, in contrast 
with Ondigo et al., concluded to the need of selecting and 
combining different antigens with different kinetics for 
improving estimates of P. falciparum exposure [53].
These combinations have been demonstrated to 
improve the accuracy and the precision of malaria infec-
tion exposure. However the technologies used (multi-
plex, microarrays or cytometry) are quite expensive and 
the required equipment is not always available (or only in 
very few, high-level laboratories) in the countries where 
monitoring of malaria infection is needed. In a country 
with limited resources, there is probably a space for the 
use of less sophisticated tools, such as ELISA assays, and 
based on the results of this study, the use of crude extract 
could be a good choice. In fact, crude extract containing 
a plurality of antigens can overcome the constraints asso-
ciated to the choice of specific antigens and give a better 
sensitivity, allowing detection of P. falciparum exposure 
in areas of low-level transmission [22, 24].
In this current study, a crude schizont extract of 
PfSch07/03 was used in ELISA to examine the dynamic of 
antibody responses in individuals living in Dielmo (Sene-
gal), an area where malaria transmission has substantially 
decreased [35]. An estimation transmission model based 
on prevalence of antibody responses against PfSch07/03 
was applied to assess the applicability of this model in the 
study area.
Results showed a significant increase both in level and 
prevalence of antibody responses with age within sur-
veys. These observations confirmed the general trend 
that anti-malaria immune responses varied with age 
in endemic areas [38]. For all age groups, comparisons 
of both OD magnitude and seropositivity prevalence 
showed that antibody level and seroprevalence were gen-
erally significantly higher in 2000 and decreased over 
time to 2012. The decreased of antibody responses cor-
related with the decrease of transmission level induced 
by control interventions deployed in Dielmo [35]. These 
results confirmed the high sensitivity of serological 
responses to detect changes in exposure to malaria infec-
tion [15, 16].
Maximum likelihood method from age-specific sero-
prevalence reversible catalytic model was used to esti-
mate seroconversion rate (SCR). SCR estimates were 
shown to correlate closely with EIR, the gold standard 
measurement of malaria transmission. The result was 
consistent with previous studies that have shown good 
correlation between EIR and SCR in low transmission 
areas [15]. Importantly, heterogeneity of SCR by time-
point survey corresponded to that of transmission in 
the study site. Indeed, the study locality has for long 
been a holoendemic malaria area in which transmission 
has varied from 142.5 (in 1990) to 482 (in 2000) infec-
tive bites/person/year [35]. A recent study in this local-
ity has shown that both transmission level and malaria 
attacks dropped since the introduction of LLINs in 
2008 combined with ACT [35]. The data showed 
the recent change about the level of transmission in 
Dielmo. Some cautiousness should be considered on 
the interpretation of the relationship between SCR and 
EIR. The variability of these measures should be taken 
into account in order to avoid misinterpretation. How-
ever, estimating the level of malaria transmission with 
the serological tool is relatively simple and could have 
an interest in the assessment of control interventions 
all the more so the antibodies response remain detect-
able for years.
SCRs obtained by combining all sectional data were 
statistically different from those obtained with time-
point survey. In cross-sectional studies, SCRs gave pre-
cise information in the level of transmission and detected 
previous changes in malaria exposure. This difference 
could be explained by the heterogeneity in the transmis-
sion in Dielmo during these periods [35] and by antibody 
responses variability [38]. In contrast, the study of Arnold 
et al. [30] found a similarity between the prospective esti-
mate of the seroconversion rate from the longitudinal 
data and that estimated from the cross-sectional survey 
using data that covered the same period (cross-sectional 
Table 5 Estimation of parameters [respectively the relative risk (RR)] influencing seroconversion and seroreversion rates 
from longitudinal studies
Covariates SCR SRR
Effect RR p value Effect RR p value
Clinical episodes 0.08 0.092 < 0.001 0.24 0.786 < 0.001
Mosquito nets − 2.57 0.076 < 0.001 0.010 1.01 < 0.001
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sample in 2012). These contrasting results could be 
explained partly by the difference of samples in these 
two studies. Indeed the samples used by Arnold et  al. 
[30] included only children aged 0–11 years old. Another 
explanation could be the dramatic reduction in malaria 
transmission over the 12 years study period, while in the 
study by Arnold et al. [30]. the transmission was constant 
over the study period.
The observation that SCR averaged over the entire 
period in the longitudinal analysis differed from the 
weighted average of the stratum-specific SCRs could 
be the consequence of the large change in SCR values 
over the study period. In view of the results in the pre-
sent study. It seemed that the use for longitudinal data of 
catalytic models with constant SCR and SRR is not suit-
able in areas with rapid decline in malaria transmission. 
In these areas models allowed for time-varying SCR and 
SRR could be more adapted for longitudinal data in order 
to take into account the changes in SCRs following the 
reduction of malaria infection exposure.
Investigation of factors which might affect the SCR 
and SRR showed that both clinical episodes and the use 
of mosquito nets had significant impact on these param-
eters. In agreement with previous studies [18] show-
ing that the incidence of the disease has a significant 
influence on the estimation of SCR, clinical episodes 
were positively associated with the SCR of antibody 
responses to PfSch07/03. Similarly, the use of mosquito 
nets reduced the risk of antibodies jumping from seron-
egative to seropositive state. This is consistent with pre-
vious studies that have shown significant decrease in the 
level of immunity in the locality after the introduction of 
LLINs [38].
Results of LRT and Wald test were in favor of the alter-
native model suggesting that the previously described 
catalytic model [15, 16] was restrictive both in cross-sec-
tional and in longitudinal studies in Dielmo. However, 
this model gave some interesting results, among which, 
the correlation between corresponding EIRs obtained 
by serological data and observed EIR (entomological 
measurement). These results suggested the applicability 
of the catalytic model to serological data. However, as 
described by Yman et al. [54] the use of catalytic model 
has some weakness such as the conversion of serologi-
cal data to binary outcomes through a threshold model 
and the choice of this threshold. Furthermore, dichoto-
mizing serological measures (seronegative vs seroposi-
tive) may lead to a loss of information due to the high 
range of serological values of the seropositive group. 
Several authors proposed alternative models using con-
tinuous serological data, as the density model [41, 42] 
or the antibody acquisition model [54]. Interestingly 
Pothin et al. have shown that while seroconversion rate 
from the catalytic model and exposure rate from the 
density model measure different quantities, a high cor-
relation has been observed between these two measures 
[43]. This consolidates the use of the catalytic model 
in this study. However, in the antibody acquisition 
model, Yman et  al. found that in settings of moderate 
and intense transmission, this model based on continu-
ous data gave better precision and accuracy compared 
to catalytic models [54], even if the authors agreed that 
this approach has some disadvantages in particular if the 
data are not log-normally distributed [54]. Arnold et al. 
proposed the use of quantitative antibody levels as a val-
uable method to measure changes in transmission or dif-
ference in exposure for pathogens that elicit a transient 
antibody response or for monitoring populations with 
very high- or very low transmission [55]. Indeed, in pre-
vious studies on the population of the present study, in 
parallel to seroprevalence estimations, quantitative anti-
body levels were measured in different age groups and 
compared between two very different periods of malaria 
transmission [38]. The results showed that the levels of 
antibody responses added complementary and valuable 
information to seroprevalence values.
Comparisons of the different methods with the same 
data could be interesting to envisage.
Conclusions
The present study underlines the capacity of serological 
responses using crude extracts of P. falciparum to detect 
changes in malaria transmission and suggests to take into 
account malaria control interventions in the estimation 
of the serological measurements of malaria transmission. 
Further investigations comparing SCRs obtained from 
recombinant antigens and especially vaccine candidates 
antigens to those obtained from crude extracts would 
provide the basis for the choice and validation of a ref-
erence serological marker to assess the level of malaria 
transmission in relation to changing epidemiology. Addi-
tionally, estimations of seroconversion rates should take 
into account the heterogeneity of the transmission within 
a study period and the methodology used for these esti-
mations should be adapted to the epidemiology context.
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